Abbott announces start of study to evaluate new device to treat recurrent atrial fibrillation
Trial supports Abbott's focus on being the best partner for electrophysiologists treating people living with atrial fibrillation
6 Aug 2020Abbott (NYSE: ABT) has announced first enrollments in the TactiFlex PAF IDE study to evaluate a new device to treat people suffering from paroxysmal atrial fibrillation (PAF), a type of irregular heartbeat. The study will evaluate the performance of the investigational TactiFlex™ Ablation Catheter, Sensor Enabled™ (SE) for people whose atrial fibrillation (AFib) symptoms are unable to be managed by medication.
More than 16 million people globally are impacted by recurrent AFib, episodes of sporadic, irregular heartbeats when the heart's upper chambers beat out of sync with the lower chambers. People suffering from AFib face a number of challenges to their quality of life, including episodes of dizziness, fatigue and shortness of breath. Long term, they also face increased risk of stroke or heart failure.
The TactiFlex PAF IDE study will enroll 355 patients at multiple sites worldwide. Patients enrolled in the trial will receive an ablation procedure using Abbott's TactiFlex Ablation Catheter, SE. Data collected from the study will be submitted to support global regulatory approvals.
Physicians use tools, such as contact force technology, during ablation procedures to help them apply the right amount of pressure to the heart tissue to improve procedural effectiveness. Additionally, physicians use magnetically sensor enabled technology, such as the TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™, for precise location and navigation within the heart.
"The TactiFlex device builds on prior generations of successful technology, giving me confidence that Abbott will continue providing options to effectively treat people living with recurrent episodes of atrial fibrillation," said Prof. Prash Sanders, director of Centre for Heart Rhythm Disorders at The Royal Adelaide Hospital in Adelaide, South Australia.
The start of the TactiFlex PAF IDE trial is among a series of product-focused activities from Abbott designed to improve patient care and meet the needs of electrophysiologists around the world. The company also recently secured U.S. Food and Drug Administration (FDA) and CE Mark approval for the EnSite™ LiveView Dynamic Display. LiveView is designed to allow data from the Advisor HD Grid mapping catheter to be visualized in real time during cardiac ablation procedures. The Advisor HD Grid catheter is designed to capture information often missed with traditional mapping catheters.
"Abbott is focused on bringing innovation to physicians that can improve how people with atrial fibrillation are treated. The TactiFlex Ablation Catheter, SE brings the best of Abbott's ablation technologies into a single catheter," said Mike Pederson, senior vice president of Abbott's electrophysiology and heart failure businesses.
The TactiFlex Ablation Catheter, SE is being clinically evaluated as part of the TactiFlex PAF IDE – a global study – and is not yet commercially available.
For more of the latest science news, straight to your inbox, become a member of SelectScience for free today>>